Skip to content
lsd.com
RecruitingPhase 2

Subanesthetic Ketamine Infusions for Depressive Symptoms in Intensive Care Unit Patients

NCT07639359 · KID-ICU · Hospital Italiano de Buenos Aires

Recruiting
Status
Accepting participants
Phase 2
Phase
50
Target enrolment
2
Study sites
1 US states

What it is testing

Summary

Depressive symptoms are common among patients admitted to the intensive care unit (ICU) and may adversely affect recovery, participation in care, treatment adherence, quality of life, and outcomes after critical illness. Conventional antidepressants have limited utility for rapidly treating depressive symptoms during an ICU admission because of their delayed onset of action and potential drug interactions in medically complex patients. Ketamine is an N-methyl-D-aspartate receptor antagonist with rapid antidepressant effects when administered intravenously at subanesthetic doses. However, evidence regarding its efficacy and safety for depressive symptoms developing during critical illness remains limited. The KID-ICU trial is a Phase II randomized, double-blind, placebo-controlled, multicenter trial evaluating subanesthetic intravenous ketamine for moderate-to-severe depressive symptoms in adult ICU patients. Eligible participants are adults who have been admitted to an ICU for 6 or more days and have a Patient Health Questionnaire-9 (PHQ-9) score of 10 or greater. Participants will be randomized in a 1:1 ratio to receive either intravenous ketamine at 0.5 mg/kg, with a maximum dose of 60 mg per infusion, administered over 60 minutes once daily for 2 consecutive days, or normal saline placebo with an identical volume, appearance, and infusion duration. The primary efficacy outcome is the change in PHQ-9 total score from baseline to Day 14 after the second scheduled infusion. Secondary outcomes include the longitudinal trajectory of PHQ-9 scores through Day 30, clinically meaningful PHQ-9 response at Day 14, anxiety and depressive symptoms assessed with the Hospital Anxiety and Depression Scale, Clinical Global Impression scores, prespecified safety events, time to ICU and hospital discharge alive, and 30-day all-cause mortality. A total of 50 participants will be enrolled across participating ICUs in Argentina. Psychiatric and clinical follow-up will be provided to all participants regardless of treatment assignment.

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

  • Change in PHQ-9 Score from Baseline to Day 14 Post-Last Infusion

    Measured over From baseline (before first infusion, Day 0) to Day 14 after the last infusion

  • Incidence of Safety Events During and After Ketamine Infusion

    Measured over During infusion and up to 240 minutes after each infusion (Days 1 and 2), and at follow-up visits (Days 1, 7, 14, and 30 post-last infusion)

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

18 Years to 99 Years
Ages
All
Sex
Not accepted
Healthy volunteers
\*\*Inclusion Criteria:\*\* * Age 18 to 99 years. * Male or female. * Admission to an intensive care unit for 6 or more days at the time of screening. * Moderate to severe depressive symptoms, defined as a Patient Health Questionnaire-9 score of 10 or greater at screening. * Ability to provide informed consent. \*\*Exclusion Criteria:\*\* * History of psychosis or hallucinations, as assessed by review of the electronic medical record and patient interview during screening. * History of prolonged QT interval. * History of dementia. * History of major depressive disorder before the current intensive care unit admission. * History of psychiatric diagnosis, including dissociative disorder, primary psychotic disorder, mania with psychosis, pervasive developmental disorder, cognitive disorder, or anorexia nervosa. * Known allergy to ketamine or diphenhydramine. * History of increased intracranial pressure, hypertensive hydrocephalus, or increased intraocular pressure. * Hemodynamic instability at the time of screening, defined as peripheral oxygen saturation \<95%, systolic blood pressure \<90 mmHg or \>180 mmHg, heart rate \<50 or \>120 beats/min, or respiratory rate \<10 or \>30 breaths/min. * Patient refusal to participate or to provide informed consent. * Pregnancy, postpartum period within 2 months, or breastfeeding. * Presence of intracranial mass or vascular lesion. * Altered mental status precluding informed consent. * Body weight \>115 kg or \<45 kg. * Active psychosis. * Current treatment with medications that may interfere with the N-methyl-D-aspartate receptor system, including lamotrigine, acamprosate, memantine, riluzole, or lithium. * Current treatment with aminophylline or theophylline. * Active substance withdrawal or use of hallucinogens, including cannabis, in the past month, as determined by clinical interview and urine drug screening.

Where

2 study sites

FacilityCityRegionCountry
Mayo ClinicJacksonvilleFloridaUnited States
Hospital Italiano de Buenos Aires - Sede CentralBuenos AiresBuenos AiresArgentina

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record. The registry also holds the most current version of everything above.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT07639359 on ClinicalTrials.gov →

Last updated in the registry 2026-09-02. Registry records change; this page reflects the data build of 2026-10-06.

Related

Where this trial sits

Substance

Recruiting in